Síntese, caracterização química e atividades biológicas de um novo derivado da Naringenina

Abstract

Investing in the development of new preventive therapies against the progression of chronic diseases is essential, since these diseases share common aetiologies such as inflammation and oxidative stress. Flavonoids such as naringenin have been the subject of several studies in the prevention, control and treatment of chronic diseases. The objective of this work was to synthesize a new chemical entity and, from this, to explore its chemical and physicochemical characteristics and its biological activities. ACD41 was synthesized from the condensation reaction between naringenin and aminoguanidine. Its chemical structure was elucidated using ESI-MS, MS-MS, NMR and FTIR techniques, and physicochemical aspects studied using TG, DSC, DTA and XRD. The biological activities explored included the trials related to oxidative stress, glycation and inflammation. ACD41 was presented as a crystalline solid, with 81% yield, 328.33 g / mol molecular mass, retention time of 12.1 minutes in HPLC analysis and with lower thermal resistance compared to naringenin. ACD41 showed low cytotoxicity with IC50 greater than 1000 μg / mL in human macrophages (THP-1) and 767.4 ± 18.71 μg / mL in human fibroblasts (MRC-5). It presented sequestering activity against the radicals ABTS+ • (IC 50 = 5.26 ± 0.10 μg / mL) and DPPH• (IC 50 = 8.33 ± 0.49 μg / mL). It reversed ROS levels and preserved mitochondrial membrane integrity in THP1. In the in vitro glycation assays, ACD41 inhibited the formation of AGEs by oxidative (IC 50 = 2.58 ± 1.67 μg / mL) and non-oxidative (IC 50 = 72.23 ± 2.28 μg / mL). In LPS-activated macrophages, it inhibited the production of TNF-α at concentrations of 5 and 10 μg / mL. ACD41 inhibited the production of hydroperoxide by 87.95% by LOX and in the in silico studies it interacted with the COX-2 enzyme, presenting a binding energy equal to -10.3 kcal / mol. The present study describes for the first time the molecule (2E) -2- [5,7-dihydroxy-2- (4-hydroxyphenyl) -2,3-dihydro-4H-chromen-4-ylidene] hydrazine carboxymidinedide And demonstrates the antioxidant, anti-inflammatory and anti-inflammatory potential of this new chemical entity, which may be promising in the development of new therapies for chronic diseases.